Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—is heading for the exit.

The Trump administration released a 72-page report Thursday outlining its take on what's driving "a chronic disease crisis" ...